Most chemotherapeutic agents induce DNA damage, leading to p53 accumulation and apoptosis. The factors that determine chemosensitivity in p53-defective tumor cells are poorly understood. We found that the p53 family member p73 is induced by a wide variety of chemotherapeutic drugs. Blocking p73 function with a dominant-negative mutant, siRNA, or homologous recombination led to chemoresistance of human tumor cells and engineered transformed cells, irrespective of p53 status. Mutant p53 can inactivate p73 and downregulation of mutant p53 enhanced chemosensitivity. These findings indicate that p73 is a determinant of chemotherapeutic efficacy in humans.
Introduction
p73 responds to at least a subset of DNA-damaging drugs (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . In the present report, we found that TAp73 The tumor suppressor protein p53 plays a critical role in apoptosis induced by DNA-damaging agents, including many anticanis induced by a wide variety of chemotherapeutic agents and that blocking TAp73 function leads to enhanced chemoresiscer drugs (Johnstone et al., 2002; Ko and Prives, 1996) . Unfortunately, at least 50% of human cancers lack functional p53. The tance. Earlier studies showed that overproduction of certain p53 mutants can (1) block chemotherapy-induced apoptosis p53 family members, p73 and p63, share significant sequence homology with p53 but, unlike p53, give rise to multiple protein and (2) block p73 function (Blandino et al., 1999; Di Como et al., 1999; Gaiddon et al., 2001; Li et al., 1998; Marin et al., 2000) . isoforms due to alternative promoter utilization and alternative mRNA splicing (Irwin and Kaelin, 2001; Melino et al., 2002) . The
Here we demonstrate that downregulation of endogenous mutant p53 enhances chemosensitivity in p53-defective tumor TA isoforms of p63 and p73 (such as p73␣ and p73␤) contain an N-terminal transactivation domain that is lacking in the correcells. Collectively, these results support a model wherein modulation of chemosensitivity by mutant p53 is due, at least in part, sponding ⌬N isoforms. The TA isoforms can transactivate p53 target genes and induce apoptosis, whereas the ⌬N isoforms to perturbation of p73 function. are dominant inhibitors of p53-responsive gene expression. Therefore, p73 and p63 can have both proapoptotic and antiResults apoptotic effects. The antiapoptotic isoforms are predicted to block the function of all three p53 family members (Ishimoto et We found that p73␣ and, to a lesser extent, p73␤, are induced by a wide variety of chemotherapeutic agents in diverse tumor al., 2002; Pozniak et al., 2000; Stiewe et al., 2002; Zaika et al., 2002) . Accordingly, overproduction of antiapoptotic p73 isocell lines ( Figure 1A and M.S.I. and W.G.K., unpublished data). In some cases, p73 induction was only revealed after titration forms can block chemotherapy-induced apoptosis in tumor cells that retain wild-type p53 (Vossio et al., 2002; experiments that examined the influence of drug dose and duration, perhaps accounting for the earlier conclusion that p73 was 2002).
It was initially reported that p73 is not induced by DNA not responsive to DNA damage (Figure 1 and M.S.I. and W.G.K., unpublished data). For certain chemotherapeutic agents, p73 damage (Kaghad et al., 1997) . Subsequently, it was shown that p73 is induced by cis-platinum and adriamycin, implying that induction was observed at low, but not high, drug concentra-S I G N I F I C A N C E p53 mediates DNA damage-induced apoptosis, but the efficacy of DNA-damaging chemotherapeutic agents is not restricted to p53 (ϩ/ϩ) tumor cells. Moreover, p53 status cannot account for preferential killing of tumor cells by chemotherapeutic agents relative to normal (p53ϩ/ϩ) cells. p73 is a p53 paralog that encodes proapoptotic (TA forms) and antiapoptotic (⌬N forms) isoforms. TAp73 levels are higher in tumor cells relative to normal cells and mutant p53 inhibits TAp73. We found that TA p73 is induced by many chemotherapeutic agents and that inhibiting TA p73 increased chemoresistance. Conversely, downregulation of mutant p53 enhanced chemosensitivity. These results suggest that p73 contributes to chemotherapy-induced apoptosis and support a model wherein mutant p53 induces chemoresistance, at least partly, through neutralization of p73. tions ( Figure 1A ). The accumulation of p73 following chemothernot due to alterations in cell cycle distribution as determined by fluorescence-activated cell sorting of propidium iodide-stained apy treatment has been shown, when studied, to be due to increased transcription and protein stabilization (Agami et al., cells (data not shown). Similar results were obtained with human foreskin fibroblasts transformed in a similar manner to these 1999; Chen et al., 2001; Gong et al., 1999; Yuan et al., 1999) .
HEK cells (data not shown). p73 DD blocks the function of both p73 and p63 (Irwin et To ask whether accumulation of p73 contributes to chemotherapy-induced apoptosis, SW480 colon carcinoma cells were al., 2000). To more clearly define the role of TA-p73 in chemotherapy-induced apoptosis, double-stranded RNA oligonucleoinfected with recombinant adenoviruses encoding GFP and either a dominant-negative p73 (p73DD) or a point mutant derivatides (siRNA) (Elbashir et al., 2001) homologous to 5 prime unique TA-p73 sequences that are missing in ⌬Np73 were used tive thereof [p73DD (L371P)]. p73DD, but not p73DD (L371P), binds to p73 and prevents it from activating p53-responsive to inhibit the accumulation of p73 in tumor cells. Transfection of p73 siRNA, but not unrelated or scrambled siRNA, led to promoters . Likewise, p73DD, but not p73DD (L371P), protected against etoposide (VP-16)-induced cell death decreased TA-p73␣ and TA-p73␤ in multiple cell lines without affecting the levels of lamin or p53 ( Figure 3A and data not as shown by an increase in adherent, viable appearing, GFPpositive cells (Figure 2A ). In contrast, no difference was obshown). p73 siRNA, but not control siRNAs, also inhibited the accumulation of TA-p73 in response to DNA damage and conserved in untreated cells expressing either p73DD or p73DD (L371P) (Figure 2A ). ferred protection against a variety of chemotherapeutic agents in both SW480 (p53R273H/p53P309S) colon cancer cells (IARC Next we sought to quantitate the effect of p73DD on chemotherapy-induced apoptosis in genetically defined transformed TP53 Database; Rodrigues et al., 1990) and U2OS (p53 wildtype) osteosarcoma cells (Figures 3B, 4A and 4B, and data not human cells. Parallel cultures of primary human embryonic kidney cells (HEK) transformed with the SV40 early region, H-Ras, shown). Notably, taxol did not increase p73 levels in SW480 cells under any condition tested (in contrast to U2OS cells) and the telomerase catalytic subunit (hTERT) were infected with retroviruses encoding p73DD or p73DDL371P (Hahn et al., ( Figure 1A and M.S.I. and W.G.K., unpublished data), and p73 siRNA did not protect SW480 cells from taxol-induced killing 1999) ( Figure 2B ). The SV40 early region encodes large T antigen, which inactivates both p53 and the retinoblastoma protein ( Figure 4A ). It is tempting to speculate that the more pronounced effects of p73 siRNA in SW480 cells relative to U2OS cells is (pRB). After selection polyclonal, early passage cells were treated with chemotherapeutic agents. Corroborating our previdue to the fact that the former have mutant p53 and the latter wild-type p53. However, a formal comparison between these ous results, expression of p73 DD inhibited chemotherapyinduced apoptosis ( Figures 2C and 2D ). These effects were two cell lines is not possible because of many other, potentially confounding, differences. specific as they were not observed in cells infected with a retrovirus encoding p73DD L371P or with an empty virus and were Likewise, p73 Ϫ/Ϫ MEFs transformed with the SV40 large T antigen (T) ϩ H-Ras were more resistant to chemotherapycells transfected with p73 siRNA. Chemotherapy-treated cells transfected with p73 siRNA formed more colonies than cells induced killing than wild-type MEFs transformed with these oncoproteins, although the effects were less dramatic than obtransfected with buffer alone or scrambled p73 siRNA ( Figure  4D ). Importantly, neither the wild-type nor scrambled p73 siRNA served with human tumor cell lines ( Figure 4C ). Whether this is due to species or cell of origin differences is unknown.
affected colony formation by untreated cells (data not shown). Similarly, chemotherapy-treated HEK cells expressing p73DD Long-term viability assays often more accurately reflect the in vivo chemosensitivity profiles of tumors (Brown and Wouters, formed more colonies than those expressing p73DDL371P (data not shown). 1999). Thus, we performed clonagenic assays using SW480 siRNA, inhibited mutant p53 accumulation ( Figure 6B ) and, in contrast to p73 siRNA, enhanced the effectiveness of chemotherapy ( Figure 6C ). This demonstrates that downmodulation of endogenous, mutant p53 levels in a human tumor cell translates into increased cell killing by chemotherapeutic agents. Similar results were obtained in C33A cervical carcinoma cells, which also contain mutant p53 ( Figure 6D and data not shown) . The effects in C33A cells were less striking than in SW480 cells, however, which likely reflects the less efficient knockdown of mutant p53 we achieved in these cells after siRNA treatment, as determined by immunoblot analysis (data not shown).
Discussion
P53 plays a central role in the apoptotic response to DNAdamaging agents. Nonetheless, the effectiveness of DNA-damaging anticancer drugs is not restricted to tumors that retain wild-type p53. Furthermore, the clinical utility of DNA-damaging chemotherapeutic agents implies that normal tissues, which retain wild-type p53, are less susceptible to apoptosis than tumor cells, which typically lack functional p53. Our findings shed light on these paradoxes by revealing a role for p73 in chemotherapy-induced apoptosis. p73 is rarely mutated in cancer. Moreover, a variety of oncogenes activate p73, leading to increased p73 levels in cancer cells relative to normal cells (Cai et al., 2000; Mai et al., 1998; Stiewe and Putzer, 2000; Zaika et al., 1999; Zaika et al., 2001) . A recent study showed that the induction of apoptosis by p53 required the presence of p73 (Flores et al., 2002) . However, our findings clearly show that p73 can induce apoptosis in tumor cells that lack functional p53. tional studies will be required to rigorously establish the degree to which this enhanced chemosensitivity is due to p73.
The interaction of mutant p53 with p73 depends upon the nature of the p53 mutation as well the status of codon 72 in As expected, the increased viability of chemotherapyp53, which can encode Arg (R) or Pro (P) due to a common treated cells transfected with p73 siRNA was due to a decreased polymorphism in the human population . In apoptosis. Caspase activation and TUNEL positivity were sigthis regard, both the p53 alleles in SW480 cells encode for Arg nificantly diminished in SW480 cells transfected with p73 siRNA at codon 72 as determined by a PCR-based assay (data not relative to cells transfected with control siRNA (Figures 5A-5C ).
shown; Harris et al., 1986) . p53 Arg72 mutants bind to p73 as The experimental overproduction of certain "gain-of-funcwell or better than the corresponding Pro72 isoforms, perhaps tion" p53 mutants, in both wild-type and p53 null tumor cells, accounting for the preferential mutation and retention of the R leads to increased chemoresistance (Blandino et al., 1999; Li allele in tumors arising in R/P germline heterozygotes (Marin et et al., 1998) . Likewise, some p53 mutants bind to and inactivate al., 2000; Brooks et al., 2000; Soulitzis et al., 2002) . In the p73 (Di Como et al., 1999; Gaiddon et al., 2001; Marin et al., accompanying manuscript, Crook and coworkers likewise re-2000, Bensaad et al., 2003) . Our findings imply that these two port that p53 Arg72 mutants are more potent inhibitors of chephenomena might be linked. As anticipated, we detected mutant motherapy-induced apoptosis than the corresponding Pro72 p53 bound to p73 in SW480 cell extracts ( Figure 6A ). Note that isoforms and provide evidence that p53 codon 72 status influsince the former is in vast excess of the latter ences clinical response to chemotherapy in man (Bergamaschi and data not shown), only a small fraction of the total pool of et al., 2003 [this issue of Cancer Cell] ). mutant p53 is bound to p73. On the other hand, when tested Our results suggest that the response to chemotherapy is before in other cell types, the majority of p73 was bound to influenced not only by p53, but instead by the status of a network mutant p53 . To ask whether endogenous that contains p53, p73, and perhaps the closely related protein mutant p53 affects chemosensitivity, SW480 cells were treated with p53 siRNA. Transfection of p53 siRNA, but not control p63. Therapeutic modulation of p73 and mutant p53 levels might T (Pab419; Harlow et al., 1981) . Each lane contained comparable amounts of be used to target the large percentage of human tumors that protein as determined by the Bradford Method. harbor p53 mutations. Intriguing in this regard are reports of Immunoprecipitations were performed essentially as described by Marin small molecules that can induce mutant p53 to adopt a wildet al. (2000), using 1.5 mg of cell extract and either anti-p73 (mixture of ERtype conformation (Bykov et al., 2002; Foster et al., 1999) . Strat-15 and ER-13), anti-p53 (mixture of PAb1801 and PAb 421), or control anti-T egies to manipulate this network of proteins, including other (Pab419) monoclonal antibodies. ER-13 and ER-15 are specific for p73 and do not crossreact with p53 . chemoresistance in human cancers.
Generation of adenoviral plasmids Experimental procedures
Bicistronic adenoviral vectors (pAdCMV) encoding GFP and p73DD were made using the AdEasy Vector System (Quantum Biotechnologies). The Cell culture and chemotherapy treatment p73DD cDNAs from pcDNA3-T7-p73DD and pcDNA3-T7-p73DD (L371P) SW480, U2OS, T98G, HCT-116, C33A human cancer cell lines and mouse were excised with HindIII and XbaI and ligated into pADembryo fibroblasts (MEFs) were grown in DMEM supplemented with 10%
Track-CMV cut with these two enzymes. The resulting plasmids were used FBS at 37ЊC in the presence of 10% CO2. Human kidney epithelial (HEK) cells to transform E. Coli strain BJ5183 in the presence of pAdEasy-1 to make were grown in MEM-␣ with 10% FBS. Camptothecin, etoposide, cisplatinum, pAd GFP-T7-p73DD and pAd GFP-T7-p73DD (L371P), respectively. Tissue doxorubicin, and taxol were dissolved according to the manufacturer's inculture supernatants from QBI-293A cells transfected with pAd GFP-T7-structions (Sigma) before addition to cell culture media. p73DD or pAd GFP-T7-p73DD (L371P) were harvested and viral particles were purified by cesium chloride centrifugation. Equivalent amounts of infecAntibodies, western immunoblots, and immunoprecipitations tious particles were used to infect SW480 cells. Immunoblot analysis was performed essentially as described before with anti-p73 (ER-15; Marin et al., 2000) , anti-p53 (DO-1, Oncogene
Generation of HEK cell lines Research), anti-Lamin (Cell Signaling Technology), anti-tubulin (clone B1.2.5, HEK cells were sequentially infected with retroviruses encoding the SV40 early region, hTERT, and G12V H-Ras as described before (Hahn et al., Sigma), anti-Ras (C20, Santa Cruz Biotechnology), anti-T7 (Novagen), or anti-The PGL3 sequence has been previously described (Elbashir et al., 2001) . All siRNA sequences were subjected to BLAST search to confirm the absence of homology to any additional known coding sequences in the human genome. Oligonucleotides were deprotected and annealed according to the manufacturer's instructions (Dharmacon). Cells were transfected with siRNA at approximately 20%-30% confluency using Oligofectamine (Invitrogen). The final concentration of siRNA was 30-100 nM, but was comparable between each sample in a given experiment. For XTT assays, cells were allowed to recover for 24 hr prior to transfer into 96-well plates. 24 hr later, cells were treated with the indicated drugs. For TUNEL and caspase activation assays, cells were allowed to recover for 48 hr prior to treatment with chemotherapy.
XTT viability assays
XTT assays (sodium 3Ј-[1-(phenylamino-carbonyl)-3,4,-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) were performed in triplicate according to the manufacturer's instructions in 96-well plates (Roche) 24, 48, and 72 hr later. The colorimetric readout in this assay reflects the number of metabolically active mitochondria, and hence viable cells, in a given well. Values were normalized relative to cells not treated with chemotherapy. Data shown are representative of three independent experiments.
Clonagenic assays SW480 cells were transfected with siRNA as described above. 48 hr later, 2 ϫ 10 4 cells were plated in triplicate in methylcellulose-DMEM media with 30% FCS containing DMSO, doxorubicin (0.02 M), or camptothecin (5 nM). Surviving colonies were counted 10-14 days later.
Apoptosis assays
For caspase activation assays, siRNA-transfected cells were harvested at the indicated time points following chemotherapy treatment and prepared according to the manufacturer's instructions (Caspase-3 Fluorometric and Caspase-8 Fluorometric Assays, R&D Systems). One hundred micrograms ments. Figure 6 . Downregulation of mutant p53 levels enhances chemosensitivity A: Extracts of SW480 cells treated with camptothecin (1 M) ("ϩ") or DMSO ("Ϫ") were immunoprecipitated with anti-p73, anti-p53, or control (anti-T) antibodies. Bound p53 was detected by anti-p53 immunoblot analysis. Similar results were obtained using SW480 cells treated with etoposide (data not shown). B: Anti-p53 immunoblot of SW480 cells transfected with siRNA directed against p53 (30 and 100 nM), luciferase (pGL3), or p73 (wild-type or scrambled [s] ). C and D: SW480 (C) and C33A (D) cells were transfected with the indicated siRNA oligonucleotides and subsequently treated with campothecin (1 M), cisplatinum (2 g/ml), or doxorubicin (2 M) for 72 hr prior to XTT analysis.
